{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:15:08Z","timestamp":1788952508333,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University Grant Commission, Govt. of India"},{"name":"All India Council for Technical Education (AICTE-NAFETIC)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ijpharm.2014.06.031","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T03:02:06Z","timestamp":1403233326000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: Preparation, characterization and antitumor activity"],"prefix":"10.1016","volume":"472","author":[{"given":"Ketan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miten","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Vavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2014.06.031_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006469621561","article-title":"The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery","volume":"18","author":"Bardelmeijer","year":"2000","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0010","article-title":"Paclitaxel solvates","author":"Benigni","year":"2005","journal-title":"Google Patents"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/0959-8049(96)00063-9","article-title":"What have we learnt thus far from mice with disrupted P-glycoprotein genes?","volume":"32","author":"Borst","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0020","series-title":"Manual of clinical oncology","author":"Casciato","year":"2009"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/10837459609029889","article-title":"Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone","volume":"1","author":"Gershanik","year":"1996","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00360-004-0462-0","article-title":"A new method to measure intestinal activity of P-glycoprotein in avian and mammalian species","volume":"175","author":"Green","year":"2005","journal-title":"J. Comp. Physiol. B"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0035","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11095-005-8418-y","article-title":"Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy","volume":"23","author":"Hariharan","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejpb.2005.05.009","article-title":"Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation","volume":"62","author":"Keck","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0045","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1161\/01.CIR.0000124063.74526.BE","article-title":"Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model","volume":"109","author":"Kim","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0050","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1158\/1078-0432.CCR-06-1352","article-title":"Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics","volume":"12","author":"Lagas","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1023\/A:1024458206032","article-title":"Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property","volume":"20","author":"Lee","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0060","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/js9605226","article-title":"Solid-state characterization of paclitaxel","volume":"86","author":"Liggins","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/smll.200500020","article-title":"Symmetric and asymmetric Ostwald ripening in the fabrication of homogeneous core\u2013shell semiconductors","volume":"1","author":"Liu","year":"2005","journal-title":"Small"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1010635000879","article-title":"Oral delivery of taxanes","volume":"19","author":"Malingr\u00e9","year":"2001","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0075","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2001.19.4.1160","article-title":"Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel","volume":"19","author":"Malingr\u00e9","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0085","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1166\/jbn.2013.1710","article-title":"Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol\u00ae","volume":"9","author":"Patel","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-014-2345-y","article-title":"Arginoplexes: an arginine-anchored nanoliposomal carrier for gene delivery","volume":"16","author":"Patel","year":"2014","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002800050032","article-title":"Pharmacokinetics and metabolism of docetaxel administered, as a 1-h intravenous infusion","volume":"45","author":"Rosing","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/17425255.2.4.591","article-title":"The road map to oral bioavailability: an industrial perspective","volume":"2","author":"Thomas","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1166\/jnn.2006.440","article-title":"Improved oral delivery of paclitaxel following administration in nanoemulsion formulations","volume":"6","author":"Tiwari","year":"2006","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejps.2008.06.009","article-title":"Drying of crystalline drug nanosuspensions\u2014the importance of surface hydrophobicity on dissolution behavior upon redispersion","volume":"35","author":"Van Eerdenbrugh","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejps.2005.04.003","article-title":"Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo","volume":"25","author":"Varma","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2014.06.031_bib0125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2012.04.001","article-title":"Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study","volume":"81","author":"Zabaleta","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517314004517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517314004517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:57:26Z","timestamp":1746273446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517314004517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":25,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0378517314004517"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2014.06.031","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: Preparation, characterization and antitumor activity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2014.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}